A New Way To Tackle Deal Valuations: Infectious Disease As A Case Study
Executive Summary
Despite regulatory uncertainty, the growing problem of antibiotic resistance – especially for gram-negative organisms – has forced big drug companies to take renewed interest in novel anti-infectives.
You may also be interested in...
Rib-X Teams With Sanofi To Develop Novel, Broad-Spectrum Antibiotics
Deal enables biotech to monetize a portion of its ribosome research while maintaining control over larger segments.
The Biopharma A List: Taking The Pulse Of Newco Creation
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.
Seven Key Success Factors In Market Opportunity Assessments
In conducting pharma market opportunity assessments, there are several best practices that exist and common mistakes to avoid. In Vivo shares expert learnings from Pharma Intelligence’s Custom Intelligence leaders.